Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Revenue (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Revenue for 7 consecutive years, with $114.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 279.52% to $114.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $139.7 million, a 120.01% increase, with the full-year FY2025 number at $139.7 million, up 120.01% from a year prior.
  • Revenue was $114.1 million for Q4 2025 at Beam Therapeutics, up from $9.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $316.2 million in Q4 2023 to a low of $6000.0 in Q1 2021.
  • A 5-year average of $34.7 million and a median of $15.0 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 851050.0% in 2021, then tumbled 90.49% in 2024.
  • Beam Therapeutics' Revenue stood at $51.1 million in 2021, then crashed by 60.76% to $20.0 million in 2022, then surged by 1478.04% to $316.2 million in 2023, then crashed by 90.49% to $30.1 million in 2024, then soared by 279.52% to $114.1 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Revenue are $114.1 million (Q4 2025), $9.7 million (Q3 2025), and $8.5 million (Q2 2025).